nimotuzumab
oncoscience,biocon,daiichi sankyo
['pancsm', 'nimotuzumab', 'pancreatic']
 #asco22 #cancerresearch shows egfr inhibitor nimotuzumab extends overall survival in kras wild-type, advanced #pancreaticcancer, esp those with no history of surgery #pancsm #surgonc
Timely, trusted, compassionate doctor-approved info from @ASCO
https://t.co/K04SLVsoar

We cannot answer individual medical questions.

Retweet ?Endorsement